en · de · es · fr · pt
liraglutide-notes.peptides6608.com › Guide › Ipamorelin Background And Receptor Selectivity — Field Notes

Ipamorelin Background And Receptor Selectivity — Field Notes

By Editorial Desk · published 2026-03-19 · last reviewed 2026-05-06 · Guide

This is a working overview of certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-05-06 and is reviewed periodically as new material appears.

Ipamorelin Background and Receptor Selectivity

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Analytical Methods and Storage Stability

Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.

Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.

Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Pentapeptide with amidated C-terminus
Molecular weight711.85 g/molMonoisotopic mass
Primary receptorGHS-R1aGhrelin receptor, Gq/11 coupled
Peptide classSynthetic pentapeptideContains two non-natural residues
Reported selectivityLower cortisol and prolactin effectObserved in animal and early human work

Ipamorelin Background and Receptor Pharmacology

Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Related pages on this site

Handling, Storage, and Analytical Characterization

Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.

Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.

Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.

Handling Storage And Analytical Control

Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.

In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.

Receptor Selectivity and Secretagogue Signaling

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.

Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.

Supporting material

According to the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party, the Chinese government directly subsidizes producers of fentanyl precursors and analogues through tax rebates and other incentives. Since 2019, the Chinese government has removed online records of subsidies for fentanyl-related producers. In 2016, federal legislation loosened the de minimis exemption, which permitted parcels under $800 in value to enter the country duty-free with minimal inspection. The change in the de minimis eligibility led to the rapid growth in parcels coming from China, including those containing fentanyl. Deaths from fentanyl in 2016 increased by 540 percent across the United States since 2013. This accounts for almost "all the increase in drug overdose deaths from 2015 to 2016", according to a study published in the Journal of the American Medical Association. Readily available fentanyl killed 70,000 people in 2021 alone. Fentanyl-laced heroin has become a big problem for major cities, including Philadelphia, Detroit and Chicago. Its use has caused a spike in deaths among users of heroin and prescription painkillers, while becoming easier to obtain and conceal. Some arrested or hospitalized users are surprised to find that what they thought was heroin was actually fentanyl. According to former CDC director Tom Frieden in 2016:

==== Database of Genotypes and Phenotypes ==== NIH sponsors the Database of Genotypes and Phenotypes (dbGaP), a repository of information produced by studies investigating the interaction of genotype and phenotype. The information includes phenotypes, molecular assay data, analyses and documents. Summary-level data is available to the general public whereas the individual-level data is accessible to researchers. According to the City Journal NIH denies access to such attributes as intelligence, education and health on the grounds that studying their genetic basis would be stigmatizing.

====== SIMS ====== Secondary-ion mass spectrometry (SIMS) is a technique similar to DESI, but while DESI is an ambient ionization technique, SIMS happens in vacuum. The solid sample surface is bombarded by a highly focused beam of primary ions. As they hit the surface, molecules are emitted from the surface and ionized. The choice of primary ions determines the size of the beam and also the extent of ionization and fragmentation. Pareek et al. performed metabolomics to trace how purines are synthesized within purinosomes and used isotope labeling and SIMS imaging to directly observe hotspots of metabolic activity within frozen HeLa cells.

Sources: en.wikipedia.org

Notes from published material

== Additives == Mobile phase pH and electrostatic interactions, as well as analyte polarity, are regulated by the addition of ionic additives. These additives improve separation efficiency, including more symmetric peaks, less peak tailing, and better recovery from the stationary phase. Ammonium acetate and ammonium formate are commonly used, as they have good solubility in high organic. When considering additive addition, compatibility with detectors is important to consider. HILIC is often used with a mass spectrometry (MS), which cannot handle non-volatile salts like sodium perchlorate, which may suppress ion signal in the instrument, though it may increase mobile phase polarity and assist with elution in HILIC.

=== In prokaryotes === Although there is far less research available on ribosomal RNA degradation in prokaryotes in comparison to eukaryotes, there has still been interest on whether bacteria follow a similar degradation scheme in comparison to the NRD in eukaryotes. Much of the research done for prokaryotes has been conducted on Escherichia coli. Many differences were found between eukaryotic and prokaryotic rRNA degradation, leading researchers to believe that the two degrade using different pathways.

Net sales for fiscal 2002 were $182 million in spite of a shaky economic climate. Bowman retired as chairman of the board in 2005, but continued to serve on the board of directors. Net sales for fiscal 2005 were $279.3 million, and by 2007 had reached $327.3 million. In 2010, Dionex was acquired by Thermo Fisher Scientific for $2.1 billion.

This side effect is in contrast to most other cytotoxic agents, which instead cause myelosuppression (bone marrow suppression), leukopenia (decreased white blood cell count), and neutropenia (decreased neutrophil count).

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is ipamorelin?

It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.

How does ipamorelin differ from ghrelin?

Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.

Is the mechanism of action fully established?

Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.

How is ipamorelin purity normally measured?

The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.

Network